Article

QLT acquires ForSight Newco II

Menlo Park, CA-The acquisition of Forsight Lab's spin-off company Forsight Newco II Inc., by QLT Inc., includes its proprietary ocular punctual plug drug-delivery system. Multiple product opportunities are a potential for this system including glaucoma treatment.

Menlo Park, CA-The acquisition of Forsight Lab's spin-off company Forsight Newco II Inc., by QLT Inc., includes its proprietary ocular punctual plug drug-delivery system. Multiple product opportunities are a potential for this system including glaucoma treatment.

"We are thrilled to be working with QLT," said Hanson S. Gifford III, chairmen of Forsight labs, and president and CEO of Forsight Newco II. "QLT's team is powerfully positioned with the experience and focus to maximize the clinical impact of this platform drug-delivery technology."

Forsight Newco II's outstanding shares cost QLT $42 million on closing, including future milestone payments and royalties on net sales of products. Milestone payments are a one time $5 million payment on the initiation of a phase III clinical trial, $20 million on first commercialization of each of the first two products using Forsight Newco II's technology and $15 million on first commercialization of each subsequent product.

Closing is expected to happen early in the fourth quarter of 2007 and is subject to customary closing conditions. Once completed Forsight Newco II will be a wholly-owned subsidiary of QLT.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.